Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1021/cb5008426 http://scihub22266oqcxt.onion/10.1021/cb5008426 C4301069!4301069 !25384187     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25384187 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25384187 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       ACS+Chem+Biol 2015 ; 10 (1 ): 225-33 Nephropedia Template TP {{tp|p=25384187 |t=2015. Drugging sphingosine kinases |pdf=|usr=}}{{25384187 }} gab.com Text Drugging sphingosine kinases JO: ACS Chem Biol http://www.kidney.de/pget.php?&tw=1&pmid=25384187 #FOAvip The transfer of the gamma phosphate from ATP to sphingosine (Sph) to generate a small signaling molecule, sphingosine 1-phosphate (S1P), is catalyzed by sphingosine kinases (SphK), which exist as two isoforms, SphK1 and SphK2. SphK is a key regulator of S1P and the S1P:Sph/ceramide ratio. Increases in S1P levels have been linked to diseases including sickle cell disease, cancer, and fibrosis. Therefore, SphKs are potential targets for drug discovery. However, the current chemical biology toolkit needed to validate these enzymes as drug targets is inadequate. With this review, we survey in vivo active SphK inhibitors and highlight the need for developing more potent and selective inhibitors. Twit Text FOAVip Drugging sphingosine kinases ????ACS Chem Biol http://www.kidney.de/pget.php?&tw=1&pmid=25384187 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25384187 #FOAvip English Wikipedia <ref>{{Cite pmid|25384187 }}</ref> Drugging sphingosine kinases #MMPMID25384187 Santos WL ; Lynch KR ACS Chem Biol 2015[Jan]; 10 (1 ): 225-33 PMID25384187 show ga The transfer of the gamma phosphate from ATP to sphingosine (Sph) to generate a small signaling molecule, sphingosine 1-phosphate (S1P), is catalyzed by sphingosine kinases (SphK), which exist as two isoforms, SphK1 and SphK2. SphK is a key regulator of S1P and the S1P:Sph/ceramide ratio. Increases in S1P levels have been linked to diseases including sickle cell disease, cancer, and fibrosis. Therefore, SphKs are potential targets for drug discovery. However, the current chemical biology toolkit needed to validate these enzymes as drug targets is inadequate. With this review, we survey in vivo active SphK inhibitors and highlight the need for developing more potent and selective inhibitors. |Adenosine Triphosphate/metabolism [MESH] |Animals [MESH] |Biocatalysis [MESH] |Ceramides/metabolism [MESH] |Drug Discovery/*methods [MESH] |Enzyme Inhibitors/chemistry/*pharmacology [MESH] |Humans [MESH] |Lysophospholipids/*metabolism [MESH] |Phosphotransferases (Alcohol Group Acceptor)/*antagonists & inhibitors/chemistry [MESH] |Signal Transduction [MESH]Drugging sphingosine kinases (epmc).pdf DeepDyve Pubget Overpricing